The Use of Homogenized Human Leukocytes for the Preparation of Anti-Lymphocyte Serum
This is the first report of the preparation of a potent antileukocyte serum produced by immunization with homogenates of human leukocytes. High titers of antibody activity were found against nuclei and a number of other intracellular materials, including
JEHN, ULRICH W., RENNER, HELMUT H.
core +1 more source
Subcutaneous Alemtuzumab as Salvage Therapy for Acute Kidney Transplant Rejection Following Thymoglobulin Anaphylaxis: A Pediatric Case Report. [PDF]
O'Connor KW +4 more
europepmc +1 more source
Severe aplastic anemia as a rare autoimmune complication of ankylosing spondylitis: A rare case report. [PDF]
Alkhen R +4 more
europepmc +1 more source
Reinterpreting the matched-sibling relapse penalty in ATG-based allogeneic transplantation for myelodysplastic neoplasms: a question of dose, not donor. [PDF]
AlJohani NI.
europepmc +1 more source
Low-Dose Antithymocyte Globulin in Type 1 Diabetes: Real-World Exploratory Observation of C-Peptide by Modified Quantitative Response (mQR). [PDF]
Weber D +7 more
europepmc +1 more source
CD4- and CD8-to-Total Lymphocyte Ratios to Guide Rabbit Anti-Thymocyte Globulin Induction in Kidney Transplant Recipients: A Single-Center Feasibility Study. [PDF]
Chen IR +12 more
europepmc +1 more source
Prophylaxis of graft-versus-host-disease: Systematic evidence-based recommendations of the Brazilian association of hematology, hemotherapy, and cell therapy (ABHH) and the Brazilian society of cellular therapy and bone marrow transplantation (SBTMO). [PDF]
Vigorito AC +8 more
europepmc +1 more source
Systematic review of emerging technologies in vascularized composite allotransplantation. [PDF]
Chakradhar A, Yu M, Talbot SG.
europepmc +1 more source
Recurrent transplant renal vein thrombosis caused by May-Thurner syndrome: a case report and review of literature. [PDF]
Kamali K +6 more
europepmc +1 more source
The Transformative Journey of Vascularized Composite Allotransplantation: Advances, Challenges, and Future Directions. [PDF]
Sonehara A +4 more
europepmc +1 more source

